Trial Profile

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olverembatinib (Primary)
Indications Gastrointestinal stromal tumours; Solid tumours
Focus Adverse reactions
Sponsors Ascentage Pharma

Most Recent Events

27 Feb 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
13 Sep 2024 Results (As of March 12, 2024, N= 26 ) presented in an Ascentage Pharma Media Release.
13 Sep 2024 According to an Ascentage Pharma media release, the company has released the clinical data of olverembatinib (HQP1351), in a Mini Oral at the 2024 European Society of Medical Oncology (ESMO) Congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com